BiotechTube
Home/AceLink Therapeutics/Li Li
LL

Li Li

VP, Operation

AceLink Therapeutics

Therapeutic Areas

Lysosomal Storage DisordersRare Genetic DiseasesRenal Diseases

AceLink Therapeutics Pipeline

DrugIndicationPhase
AL01211Fabry disease; Type I Gaucher diseasePhase 2
AL0804Neuronopathic Gaucher disease (Types II/III); GM1/GM2 Gangliosidosis; Genetic Parkinson'sPreclinical
AL1311Autosomal Dominant Polycystic Kidney Disease (ADPKD)Preclinical

Leadership Team at AceLink Therapeutics

WC
Wen Chen
CEO
JZ
Jianhong Zheng
VP and GM, China Operation
MB
Michael Babcock
VP, Research and Early Development
View full AceLink Therapeutics profile